de Baere T, Roche A, Elias D, Lasser P, Lagrange C, Bousson V
Department of Interventional Radiology, Institut Gustave Roussy, Villejuif, France.
Hepatology. 1996 Dec;24(6):1386-91. doi: 10.1053/jhep.1996.v24.pm0008938166.
To render hepatectomy feasible in patients with an initially deficient volume of the future remnant liver (FRL), we redistributed portal blood flow rich in hepatotrophic substances toward the FRL. Redistribution was achieved with preoperative portal vein embolization (POPE) feeding the future resected liver. POPE was performed in 31 patients, under fluoroscopic guidance, via a percutaneous access. POPE was well tolerated and surgery was practicable in 24 patients without severe postoperative liver failure. Seven operations were cancelled, but only one due to insufficient hypertrophy of the FRL. FRL volume values were 90 to 560 mL (mean 260 mL) before POPE and 160-783 mL (mean 443 mL) after POPE, which represents a median increase of 79% +/- 50%. Hypertrophy of the FRL was 90% +/- 52% after 30 days with cyanoacrylate, 53% +/- 6% after 43 days with Gelfoam, and 44% +/- 30% after 35 days with coils. Slight shrinkage was obtained in the volume of the embolized liver, for which resection was planned. Overall survival was 2-62 months (mean 26 months), disease-free survival was 0-60 months (mean 19 months), and 7 patients are disease-free and alive 14 to 60 months (mean 43 months) after surgery. Although exclusively applicable in a limited subset of patients, POPE widens the possibilities of curative hepatectomies, because it induces sound hypertrophy of unembolized liver segments. Cyanoacrylate seems to ensure better and faster hypertrophy.
为使初始未来剩余肝(FRL)体积不足的患者能够进行肝切除术,我们将富含肝细胞营养物质的门静脉血流重新分配至FRL。通过术前门静脉栓塞术(POPE)向未来拟切除的肝脏供血来实现血流重新分配。31例患者在透视引导下经皮穿刺进行了POPE。POPE耐受性良好,24例患者可行手术且未发生严重术后肝衰竭。7例手术取消,但仅1例是由于FRL肥大不足。POPE术前FRL体积值为90至560 mL(平均260 mL),术后为160 - 783 mL(平均443 mL),中位数增加79%±50%。使用氰基丙烯酸酯30天后FRL肥大率为90%±52%,使用明胶海绵43天后为53%±6%,使用弹簧圈35天后为44%±30%。计划切除的栓塞肝脏体积略有缩小。总生存期为2至62个月(平均26个月),无病生存期为0至60个月(平均19个月),7例患者术后14至60个月(平均43个月)无病存活。尽管POPE仅适用于有限的一部分患者,但它拓宽了根治性肝切除术的可能性,因为它能诱导未栓塞肝段产生良好的肥大。氰基丙烯酸酯似乎能确保更好、更快的肥大。